Glaxo executive opposes splitting FDA reviews

GlaxoSmithKline's R&D chairman opposes creation of a separate agency to monitor the safety of FDA-approved drugs. Tachi Yamada said splitting the process is a hazardous idea and drugs should be reviewed in their totality. Separately, a Journal and Constitution editorial supports the proposal to create an agency independent of the FDA because the agency no longer has the trust of the public.

View Full Article in:

Reuters · Journal and Constitution (Atlanta) (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX